Financials
- Market Capitalization 2.51 B
- Employee 47
- Founded 1998
- CEO Helen Sabzevari
- Website www.precigen.com
- Headquarter Virginia, United States
- FIGI BBG000QL8VH9
- Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-3.05
Relación precio/flujo de caja
135.09
Related tickers
| # | Nombre | Precio | 24h % | 7d % | 1M % | 1A % | Capitalización | Últimos 7 días | |
|---|---|---|---|---|---|---|---|---|---|
| 1814 | VRDN Viridian Therapeutics, Inc. - Common Stock | 23.18 USD | -2.93% | -4.14% | +18.51% | +3.25% | 2.63 B USD | ||
| 1837 | RARE Ultragenyx Pharmaceutical Inc. - Common Stock | 25.87 USD | -1.49% | -0.73% | +0.39% | -14.54% | 2.55 B USD | ||
| 1861 | NKTR Nektar Therapeutics - Common Stock | 71.51 USD | -4.08% | -4.03% | +0.45% | -2.40% | 2.44 B USD | ||
| 1862 | BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | 9.80 USD | -0.71% | +2.40% | +1.45% | +15.84% | 2.50 B USD |